CeNeS Licenses MS Treatment to Acorda

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 31 (Table of Contents)

Published: 2 Dec-2002

DOI: 10.3833/pdr.v2002.i31.963     ISSN: 1756-7874

Section: Licensing

Fulltext:

Abstract

CeNeS Pharmaceuticals licensed its preclinical recombinant GGF2 protein for treating multiple sclerosis to Acorda Therapeutics...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details